A groundbreaking drug , retatrutide, is sparking considerable anticipation within the Aussie weight management community. Developed by Lilly , this dual GIP and GLP-1 receiver appears to offer more substantial benefits than current therapies. Initial scientific trials have shown noteworthy reductions in physical weight , raising the for a different